FDA Approves Datopotamab Deruxtecan-dlnk for Unresectable or Metastatic TNBC
esmo -
AI Summary: Regulators have approved datopotamab deruxtecan for patients with unresectable or metastatic triple‑negative breast cancer, offering a new targeted option where few exist. The decision follows trial evidence of meaningful anti‑tumor activity and expands the treatment toolkit for aggressive TNBC subtypes, with clinicians weighing sequencing and toxicity management.
Related Stories
Bristol Myers Squibb wins first-in-class approval for protein‑degrader myeloma therapy / 15 days
Belzutifan plus pembrolizumab gains approval for adjuvant RCC / 5 wks
FDA approves belzutifan (Welireg) plus pembrolizumab for adjuvant RCC / 2 months
FDA clears first all-oral regimen for certain newly diagnosed AML patients / 2 months
VOLGA Phase III shows survival benefit for bladder cancer neoadjuvant combo / 3 months
FDA expands approval of Lu‑177 radiopharmaceutical for prostate cancer / 22 days
FDA clears Trodelvy alone and with Keytruda for first-line TNBC / 2 months
StackHealth RSS
You can now follow topics by RSS - browse the complete list of topics, people, and organizations. Or, try Corporate Takeover, Biotech, Pediatric Oncology, Neuroscience and look for the RSS link.
StackHealth Time Machine